Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Arvinas (NASDAQ: ARVN), a clinical-stage biotechnology company focused on developing targeted protein degradation drugs, has scheduled its first quarter 2025 financial results announcement and corporate update for Thursday, May 1, 2025, at 8:00 a.m. ET. The company will host a live webcast accessible through the 'Events and Presentations' section of their investor relations webpage. A recording of the webcast will be made available on www.arvinas.com after the event.
Arvinas (NASDAQ: ARVN), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di farmaci per la degradazione mirata delle proteine, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 e un aggiornamento aziendale per giovedì 1 maggio 2025, alle 8:00 ET. La società trasmetterà una diretta web accessibile tramite la sezione 'Eventi e Presentazioni' della pagina dedicata agli investitori. Una registrazione della trasmissione sarà disponibile su www.arvinas.com dopo l'evento.
Arvinas (NASDAQ: ARVN), una empresa biotecnológica en etapa clínica centrada en el desarrollo de fármacos para la degradación selectiva de proteínas, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 y una actualización corporativa para el jueves 1 de mayo de 2025 a las 8:00 a.m. ET. La compañía realizará una transmisión en vivo accesible a través de la sección 'Eventos y Presentaciones' en la página web de relaciones con inversores. Una grabación de la transmisión estará disponible en www.arvinas.com después del evento.
Arvinas (NASDAQ: ARVN)는 표적 단백질 분해 약물 개발에 주력하는 임상 단계의 바이오테크 기업으로, 2025년 1분기 재무 실적 발표 및 기업 업데이트를 2025년 5월 1일 목요일 오전 8시(동부시간)에 예정하고 있습니다. 회사는 투자자 관계 웹페이지의 '이벤트 및 발표' 섹션을 통해 실시간 웹캐스트를 진행할 예정이며, 행사 종료 후 www.arvinas.com에서 녹화 영상을 제공할 예정입니다.
Arvinas (NASDAQ : ARVN), une société biotechnologique en phase clinique spécialisée dans le développement de médicaments ciblant la dégradation des protéines, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 et une mise à jour d'entreprise pour le jeudi 1er mai 2025 à 8h00 ET. La société diffusera un webinaire en direct accessible via la section « Événements et Présentations » de sa page relations investisseurs. Un enregistrement du webinaire sera disponible sur www.arvinas.com après l'événement.
Arvinas (NASDAQ: ARVN), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung zielgerichteter Proteinabbau-Medikamente spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 sowie ein Unternehmensupdate für Donnerstag, den 1. Mai 2025, um 8:00 Uhr ET geplant. Das Unternehmen wird ein Live-Webcast anbieten, der über den Bereich „Veranstaltungen und Präsentationen“ auf der Investor-Relations-Webseite zugänglich ist. Eine Aufzeichnung des Webcasts wird nach der Veranstaltung auf www.arvinas.com verfügbar sein.
- None.
- None.
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET.
The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC® (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
When will Arvinas (ARVN) release Q1 2025 earnings?
How can investors access Arvinas' Q1 2025 earnings webcast?
What is Arvinas' main business focus?
Will there be a replay available of Arvinas' Q1 2025 earnings call?
